ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VCEL vs BCRX // EV/EBITDA & P/E VALUATION

Vericel Corporation (NASDAQ) VS. BioCryst Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: VCEL 2 — BCRX 5
▲ EV/EBITDA & P/E VALUATION LEADER: BCRX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCEL VS. BCRX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VCEL BCRX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 74.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 3.40% 85.00% -81.60 BCRX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 61.4x 6.1x +55.30 BCRX /valuation <GO>
Free Cash Flow Yield 1.13% 15.96% -14.83 BCRX /fcf-yield <GO>
Operating Margin 4.00% — — TIE /operating-margins <GO>
Net Profit Margin 6.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 16.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 9.94 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 6/9 +2.00 VCEL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.2 54.8 -8.66 BCRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 111.7x 7.7x +104.00 BCRX /forward-pe <GO>
Enterprise Scale & Market Cap $2.20B $2.18B $20.1M VCEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VCEL REV BCRX REV VCEL GROSS % BCRX GROSS % VCEL FCF BCRX FCF
FY 2025 $276.3M $0 74.4% — $24.7M $347.4M
FY 2024 $237.2M $0 72.6% — -$5.8M -$52.0M
FY 2023 $197.5M $0 — — $35.3M -$95.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCEL // BETA —
BCRX // BETA —